# UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF ILLINOIS EASTERN DIVISION

CUMBERLAND PHARMACEUTICALS INC.,	)
Plaintiff,	)
v.	)
MYLAN INSTITUTIONAL LLC, and	)
MYLAN INC.,	)
Defendants.	)

No. 1:12-cv-03846

JUDGE REBECCA PALLMEYER

MAGISTRATE JUDGE MARIA VALDEZ

## JOINT STIPULATION OF INFRINGEMENT

Plaintiff Cumberland Pharmaceuticals Inc. ("Cumberland") and defendants Mylan Institutional LLC and Mylan Inc. (collectively "Mylan"), appearing through counsel, hereby state that:

WHEREAS Mylan filed Abbreviated New Drug Application No. 203624 with the Food and Drug Administration ("FDA") under 21 U.S.C. § 355(j), to obtain approval for the commercial manufacture, use and sale of Acetylcysteine, Injectable; Intravenous, 200mg/ml ("Mylan Acetylcysteine Intravenous");

WHEREAS Cumberland has asserted that the filing of Mylan's ANDA No. 203624 infringes Cumberland's U.S. Patent No. 8,148,356 ("356 patent") and U.S. Patent No. 8,399,445 ("445 patent") under 35 U.S.C. § 271(e)(2)(A), and that the commercial manufacture, use and sale of the Mylan Acetylcysteine Intravenous product will infringe the '356 patent and the '445 patent under 35 U.S.C. § 271(a), (b);

#### Case: 1:12-cv-03846 Document #: 248 Filed: 08/04/14 Page 2 of 5 PageID #:8643

WHEREAS the Court has construed certain claims of the '356 patent and the '445 patent in its claim construction opinion and order (D.I. 187);

WHEREAS Mylan objects to the Court's claim construction opinion and order (D.I. 187);

WHEREAS in the interest of streamlining this litigation and the issues for trial, the parties desire to forgo litigating the issue of whether or not the commercial manufacture, use, offer to sell, sale, or importation of the product described in Mylan's ANDA No. 203624 would infringe claims 2 and 14 of the '356 patent or claims 1-14 of the '445 patent under 35 U.S.C. §§ 271(a) and/or (b) under the Court's claim construction opinion (D.I. 187) dated February 26, 2014;

IT IS HEREBY STIPULATED by the parties, subject to the approval of the Court, that the following facts and issues are undisputed and admitted for purposes of this action:

Without prejudice to any other claim or defense Mylan has in this action,
Mylan stipulates and agrees as follows:

a. Mylan will not assert before this Court or on appeal that the commercial manufacture, use, sale, offer for sale, or importation of the product described in Mylan's ANDA No. 203624 does not or would not infringe claims 2 and 14 of the '356 patent or claims 1-14 of the '445 patent under 35 U.S.C. §§ 271(a) and/or (b) under the Court's claim construction opinion (D.I. 187) dated February 26, 2014. Mylan retains the right to assert in this Court or on appeal that it is not liable for infringing any such claim if any such claim is found to be

2

unenforceable or invalid under the Patent Laws of the United States, 35 U.S.C. § 100 *et seq*;

- b. Mylan consents to the entry of a judgment in this action that Mylan's submission of ANDA No. 203624 to the FDA constitutes infringement of the '356 and '445 patents under 35 U.S.C. § 271(e)(2)(A) to the extent that any one of the claims 2 and 14 of the '356 patent or any one of the claims 1-14 of the '445 is not found to be unenforceable or invalid under the Patent Laws of the United States, 35 U.S.C. § 100 *et seq*; and
- c. Mylan consents to the entry of a judgment in this action that the commercial manufacture, use, sale, offer for sale or importation of the product described in Mylan's ANDA No. 203624, or inducement of or contribution to any such conduct, does and would infringe claims 2 and 14 of the '356 patent and claims 1-14 of the '445 patent under 35 U.S.C. §§ 271(a), (b) under the Court's claim construction opinion (D.I. 187) dated February 26, 2014, to the extent that any such claim is not found to be unenforceable or invalid under the Patent Laws of the United States, 35 U.S.C. § 100 *et seq*.

2. Mylan makes this stipulation without prejudice or waiver of its rights to appeal the Court's February 26, 2014, Claim Construction Order (D.I. 187).

### Case: 1:12-cv-03846 Document #: 248 Filed: 08/04/14 Page 4 of 5 PageID #:8645

Dated: August 4, 2014

Mylan Institutional LLC and Mylan Inc.

By: /s/ Elham F. Steiner Steven P. Mandell (ARDC #6183729) Steven L. Baron (ARDC #6200868) Elizabeth Morris (ARDC #6297239) MANDELL MENKES LLC 1 N. Franklin, Suite 3600 Chicago, IL 60606 Telephone: 312-251-1000 Facsimile: 312-251-1010

Of Counsel:

Nicole Stafford (nstafford@wsgr.com) Robert A. Delafield II (bdelafield@wsgr.com) WILSON SONSINI GOODRICH & ROSATI PROFESSIONAL CORPORATION 900 South Capital of Texas Highway Las Cimas IV, Fifth Floor Austin, Texas 78746-5546 Telephone: 512-338-5400 Facsimile: 512-338-5499

Elham F. Steiner (esteiner@wsgr.com) Wendy Devine (wdevine@wsgr.com) WILSON SONSINI GOODRICH & ROSATI PROFESSIONAL CORPORATION 12235 El Camino Real, Suite 200 San Diego, California 92130 Telephone: 858-235-2300 Facsimile: 858-350-2399

Nancy Zhang (nzhang@wsgr.com) WILSON SONSINI GOODRICH & ROSATI PROFESSIONAL CORPORATION 650 Page Mill Road Palo Alto, California 94304-1050 Telephone: 650-849-3073

Attorneys for Defendants Mylan Institutional LLC and Mylan Inc. Respectfully submitted,

CUMBERLAND PHARMACEUTICALS INC.

By: /s/ Amy Y. Cho

Laura P. Masurovsky *pro hac vice* Mark J. Feldstein *pro hac vice* Danielle A. Duszczyszyn *pro hac vice* Finnegan, Henderson, Farabow, Garrett, & Dunner, LLP 901 New York Ave, NW Washington, D.C. 20001-4413 Telephone: (202) 408-4000 Facsimile: (202) 408-4400 laura.masurovsky@finnegan.com mark.feldstein@finnegan.com danielle.duszczyszyn@finnegan.com

Lynn H. Murray Anna S. Knight Amy Y. Cho GRIPPO & ELDEN LLC 111 South Wacker Drive Chicago, IL 60606 Telephone: (312) 704-7700 Fax: (312) 558-1195 Imurray@grippoelden.com aknight@grippoelden.com

Attorneys for Plaintiff Cumberland Pharmaceuticals Inc.

## **CERTIFICATE OF SERVICE**

The undersigned certifies that on August 4, 2014, a true and correct copy of **JOINT STIPULATION OF INFRINGEMENT** was filed with the Clerk of the Court using the Electronic Case Filing (ECF) system, which will send notification of such filing via electronic mail to the following counsel of record:

Nicole W. Stafford Robert A. Delafield II WILSON SONSINI GOODRICH & ROSATI, PC 900 South Capital of Texas Highway Las Cimas IV, Fifth Floor Austin, TX 78746-5546 Tel: (512) 338-5400 Fax: (512) 338-5499

Nancy L. Zhang WILSON SONSINI GOODRICH & ROSATI, PC 650 Page Mill Road Palo Alto, CA 94304-1050 Tel: (650) 849-3073 Fax: (650) 493-6811

Tung-On Kong WILSON SONSINI GOODRICH & ROSATI, PC One Market Plaza, Spear Tower, Suite 3300 San Francisco, CA 94105 Tel: (415) 947-2000 Fax: (866) 974-7329 Stuart A. Williams WILSON SONSINI GOODRICH & ROSATI, PC 1301 Avenue of the Americas, 40th Floor New York, NY 10019 Tel: (212) 497-7705 Fax: (212) 999-5899

Wendy L. Devine Elham F. Steiner WILSON SONSINI GOODRICH & ROSATI, PC 12235 El Camino Real, Suite 200 San Diego, CA 92130 Tel: (858) 350-2321 Fax: (858) 350-2399

Steven P. Mandell Steven L. Baron Elizabeth Morris Stephen J. Rosenfeld MANDELL MENKES LLC 1 North Franklin, Suite 3600 Chicago, IL 60606 Tel: (312) 251-1000 Fax: (312) 251-1010

Attorneys for Mylan Institutional LLC and Mylan Inc.

/s/ Amy Y. Cho